Publications by authors named "Jennifer Leeds"

Claim this Profile
W
When passion is not enough: the waning of the infectious disease workforce.
Jennifer A Leeds

mSphere· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
and Properties of CUO246, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor.
Johanne Blais, Charles R Dean, Guillaume Lapointe, Jennifer A Leeds, Sylvia Ma

Antimicrob Agents Chemother· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive Bacteria.
Guillaume Lapointe, Colin K Skepper, Lauren M Holder, Duncan Armstrong, Cornelia Bellamacina, Jennifer A Leeds

J Med Chem· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Novel Antibiotics as Covalent Inhibitors of Fatty Acid Synthesis.
Jia Wang, Xiaoping Ye, Xiaohan Yang, Youyan Cai, Shengjun Wang, Jennifer A Leeds

ACS Chem Biol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topoisomerase Inhibitors Addressing Fluoroquinolone Resistance in Gram-Negative Bacteria.
Colin K Skepper, Duncan Armstrong, Carl J Balibar, Daniel Bauer, Cornelia Bellamacina, Jennifer A Leeds

J Med Chem· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspective on Antibacterial Lead Identification Challenges and the Role of Hypothesis-Driven Strategies.
Laura L McDowell, Cheryl L Quinn, Jennifer A Leeds, Jared A Silverman, Lynn L Silver

SLAS Discov· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Activity of LYS228, a Novel Monobactam Antibiotic, against Multidrug-Resistant Enterobacteriaceae.
Johanne Blais, Sara Lopez, Cindy Li, Alexey Ruzin, Srijan Ranjitkar, Jennifer A Leeds

Antimicrob Agents Chemother· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances and challenges in bacterial compound accumulation assays for drug discovery.
David A Six, Thomas Krucker, Jennifer A Leeds

Curr Opin Chem Biol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosing antimicrobial resistance.
Carey-Ann D Burnham, Jennifer Leeds, Patrice Nordmann, Justin O'Grady, Jean Patel

Nat Rev Microbiol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcellular Chemical Imaging of Antibiotics in Single Bacteria Using C-Secondary Ion Mass Spectrometry.
Hua Tian, David A Six, Thomas Krucker, Jennifer A Leeds, Nicholas Winograd

Anal Chem· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibacterial and Solubility Optimization of Thiomuracin A.
Matthew J LaMarche, Jennifer A Leeds, Jason Brewer, Karl Dean, Jian Ding

J Med Chem· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.
Jennifer A Leeds

Cold Spring Harb Perspect Med· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of ciprofloxacin dimers for evaluation of bacterial permeability in atypical chemical space.
Audrey G Ross, Bret M Benton, Donovan Chin, Gianfranco De Pascale, John Fuller, Jennifer A Leeds

Bioorg Med Chem Lett· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections.
Suraj G Bhansali, Kathleen Mullane, Lillian S L Ting, Jennifer A Leeds, Kristina Dabovic

Antimicrob Agents Chemother· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections.
Kathleen Mullane, Christine Lee, Adam Bressler, Martha Buitrago, Karl Weiss, Jennifer A Leeds

Antimicrob Agents Chemother· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subinhibitory concentrations of LFF571 reduce toxin production by Clostridium difficile.
Meena Sachdeva, Jennifer A Leeds

Antimicrob Agents Chemother· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibacterial activity of enrofloxacin and ciprofloxacin derivatives of β-octaarginine.
Nirupam Purkayastha, Stefania Capone, Albert K Beck, Dieter Seebach, Jennifer Leeds

Chem Biodivers· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deletion of the β-acetoacetyl synthase FabY in Pseudomonas aeruginosa induces hypoacylation of lipopolysaccharide and increases antimicrobial susceptibility.
David A Six, Yanqiu Yuan, Jennifer A Leeds, Timothy C Meredith

Antimicrob Agents Chemother· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin.
Jennifer A Leeds, Meena Sachdeva, Steve Mullin, S Whitney Barnes, Alexey Ruzin

J Antimicrob Chemother· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers.
Lillian S L Ting, Jens Praestgaard, Nicole Grunenberg, Jenny C Yang, Jennifer A Leeds

Antimicrob Agents Chemother· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pseudomonas aeruginosa directly shunts β-oxidation degradation intermediates into de novo fatty acid biosynthesis.
Yanqiu Yuan, Jennifer A Leeds, Timothy C Meredith

J Bacteriol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fatty acid biosynthesis in Pseudomonas aeruginosa is initiated by the FabY class of β-ketoacyl acyl carrier protein synthases.
Yanqiu Yuan, Meena Sachdeva, Jennifer A Leeds, Timothy C Meredith

J Bacteriol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of LFF571 in a hamster model of Clostridium difficile infection.
Anna Trzasko, Jennifer A Leeds, Jens Praestgaard, Matthew J Lamarche, David McKenney

Antimicrob Agents Chemother· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibiotic optimization and chemical structure stabilization of thiomuracin A.
Matthew J LaMarche, Jennifer A Leeds, Joanne Dzink-Fox, Eric Gangl, Philipp Krastel

J Med Chem· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of LFF571: an investigational agent for Clostridium difficile infection.
Matthew J LaMarche, Jennifer A Leeds, Adam Amaral, Jason T Brewer, Simon M Bushell

J Med Chem· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis